Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA NA vaccine
- Development stage
- Phase 1
- Lead developer
- Sanofi Pasteur
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA NA vaccine is an investigational messenger ribonucleic acid (mRNA) vaccine developed by Sanofi Pasteur. It is administered as an intramuscular injection and is being evaluated for its safety and immunogenicity. The 'NA' in its name suggests it targets the neuraminidase antigen, likely for influenza prevention, as indicated by its comparison to a quadrivalent influenza vaccine in a clinical trial. The vaccine is formulated as a suspension for injection.
- Other names
- Monovalent mRNA NA Vaccine
02
Targets
Host ribosomal translation machineryNeuraminidase
Beyond the preview
Go deeper on mRNA NA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA NA vaccine.